Status:
NOT_YET_RECRUITING
Comparison of Sugammadex and Neostigmine During PACU Stay
Lead Sponsor:
University of South Florida
Conditions:
Neuromuscular Blockade
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Sugammadex was approved for post-operative use in the operating room (OR) and post-anesthesia recovery unit (PACU) of our quaternary facility, Tampa General Hospital. The approval came with administra...
Detailed Description
Primary Objective: * To evaluate the Length of Stay (LOS) in the PACU after a neuromuscular reversal with Sugammadex in comparison with Neostigmine/Glycopyrrolate in abdominal surgeries (hernia, gall...
Eligibility Criteria
Inclusion
- 18-75 years of age
- Patients with surgeries with duration of 90-120 minutes
- ASA Patients I-III (Appendix A)
- Patients admitted to TGH for abdominal hernia repair, cholecystectomy and/or abdominal surgery as performed by Dr. Albrink
- BMI \> 30
Exclusion
- \<18 years of age
- ASA Patients IV and above (Appendix A)
- Patients with allergic reactions to Neostigmine+Glycopyrrolate and/or Sugammadex
Key Trial Info
Start Date :
October 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 15 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04096144
Start Date
October 15 2019
End Date
June 15 2020
Last Update
September 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tampa General Hospital
Tampa, Florida, United States, 33606